the present invention is further described in details with the accompanying drawings and embodiments . the following embodiments are shown and described for the purposes of illustrating the functional and structural principles of the present invention and is subject to change without departure from such principles . therefore , this invention includes all modifications encompassed within the spirit and scope of the present invention . according to a method of synthesizing ferrate composite pharmaceutical of the preferred embodiment of the present invention , the process comprises the following steps : ( a ) weight and obtain iron salts , activating agents , alkalinizing agents and oxidizing agents solution , where the molar ratio of iron salts and activating agents is 1 : 0 . 001 ˜ 10 , the molar ratio of iron salts and alkalinizing agents is 1 : 2 ˜ 20 , the molar ratio of iron salts and oxidizing agents in the oxidizing agents solution is 1 : 0 . 1 ˜ 10 ; ( b ) mixing uniformly the iron salts , the activating agents and the alkalinizing agents obtained from step ( a ), heating to a heating temperature of 30 ˜ 398 ° c . and maintaining for a time period of 1 min ˜ 60 min to obtain a mixture ; ( c ) adding the oxidizing agents solution from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 10 minutes , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with water and stirring evenly to obtain ferrate products , which is used as a ferrate composite pharmaceutical , where the volume ratio of the precursor and the water is 1 : 1 ˜ 5 . it is worth mentioning that the ferrate composite pharmaceutical produced by the method of the present invention can also be used for other purposes , such as drinking water treatment , wastewater treatment and etc . preferably , in the step ( d ), the process of natural cooling is cooling to room temperature . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( a ), the iron salts refer to a composition containing one or more of : ferric chloride , ferrous chloride , ferric nitrate , ferrous nitrate , ferric sulfate and ferrous sulfate . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( a ), the activating agents refers to one or more of : potassium permanganate , potassium dichromate , potassium chlorate , persulfate and monopersulfates . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( a ), the alkalinizing agents refers to one or more of : sodium hydroxide , sodium carbonate , sodium bicarbonate , potassium hydroxide , potassium bicarbonate and potassium carbonate . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( a ), the oxidizing agents refers to one or more of : potassium permanganate , potassium dichromate , hydrogen peroxide , ozone , sodium hypochlorite , potassium hypochlorite , potassium chlorate , perchlorate , persulfate and monopersulfate . the concentration of the oxidizing agents solution is 0 . 1 mol / l ˜ 3 mol / l . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiments 1 - 5 except the followings : in step ( a ), the concentration of the oxidizing agents solution is 1 . 5 mol / l . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( b ), the heating temperature is 31 ° c .˜ 150 ° c . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( b ), the heating temperature is 151 ° c .˜ 397 ° c . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( b ), the time period is 8 min ˜ 10 min . according to a method of synthesizing ferrate of this preferred embodiment of the present invention , all the steps and parameters are the same as that of embodiment 1 except the followings : in step ( b ), the time period is 25 min ˜ 30 min . the advantageous effect of the method of synthesizing ferrate of the present invention is tested and verified by the followings : according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric nitrate , 0 5 g of potassium dichromate , 2 . 2 g of potassium hydroxide and 5 ml of 1 . 5 mol / l hydrogen peroxide solution ; ( b ) mixing uniformly the ferric nitrate , the potassium dichromate and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 300 ° c . and maintaining for a time period of 5 min to obtain a mixture ; ( c ) adding the 5 ml of hydrogen peroxide solution ( 1 . 5 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 0 . 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 73 ˜ 75 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 0 g of ferric sulfate , 0 5 g of activating agent , 2 . 2 g of potassium hydroxide and 3 ml of 3 mol / l hydrogen peroxide solution , where the activating agent is a mixture of potassium persulfate and potassium permanganate of which the mass ratio of potassium persulfate and potassium permanganate is 4 : 1 ; ( b ) mixing uniformly the ferric sulfate , the activating agent and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 200 ° c . and maintaining for a time period of 7 . 5 min to obtain a mixture ; ( c ) adding the 3 ml of hydrogen peroxide solution ( 3 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 0 . 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 90 ˜ 93 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric nitrate , 0 5 g of activating agent , 2 . 2 g of potassium hydroxide and 5 ml of 2 mol / l sodium hypochlorite solution ; where the activating agent is a mixture of potassium dichromate and potassium chlorate of which the mass ratio of potassium dichromate and potassium chlorate is 3 : 2 ; ( b ) mixing uniformly the ferric nitrate , the activating agent and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 150 ° c . and maintaining for a time period of 10 min to obtain a mixture ; ( c ) adding the 5 ml of sodium hypochlorite solution ( 2 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 0 . 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 83 ˜ 86 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric nitrate , 0 5 g of activating agent , 2 . 2 g of potassium hydroxide and 5 ml of 1 . 5 mol / l perchloric acid solution , where the activating agent is a mixture of potassium dichromate and peroxydisulfates of which the mass ratio of potassium dichromate and peroxydisulfates is 2 : 3 ; ( b ) mixing uniformly the ferric nitrate , the activating agent and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 350 ° c . and maintaining for a time period of 5 min to obtain a mixture ; ( c ) adding the 5 ml of perchloric acid solution ( 1 . 5 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 2 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 90 ˜ 93 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric nitrate , 0 5 g of activating agent , 2 . 2 g of potassium hydroxide and 5 ml of 0 . 1 mol / l ozone solution , where the activating agent is a mixture of potassium dichromate and monopersulfate of which the mass ratio of potassium dichromate and monopersulfate is 1 : 4 ; ( b ) mixing uniformly the ferric nitrate , the activating agent and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 40 ° c . and maintaining for a time period of 5 min to obtain a mixture ; ( c ) adding the 5 ml of ozone solution ( 0 . 1 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 0 . 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 86 ˜ 90 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric chloride , 0 5 g of potassium permanganate , 2 . 2 g of potassium hydroxide and 5 ml of 2 mol / l potassium hypochlorite solution ; ( b ) mixing uniformly the ferric chloride , the potassium permanganate and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 300 ° c . and maintaining for a time period of 5 min to obtain a mixture ; ( c ) adding the 5 ml of potassium hypochlorite solution ( 2 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 1 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 10 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 91 ˜ 93 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric chloride , 0 5 g of potassium dichromate , 2 . 2 g of potassium hydroxide and 5 ml of 1 . 5 mol / l hydrogen peroxide solution ; ( b ) mixing uniformly the ferric chloride , the potassium dichromate and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 200 ° c . and maintaining for a time period of 15 min to obtain a mixture ; ( c ) adding the 5 ml of hydrogen peroxide solution ( 1 . 5 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 0 . 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 82 ˜ 84 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric chloride , 0 5 g of potassium dichromate , 2 . 2 g of sodium carbonate and 5 ml of 1 . 5 mol / l potassium persulfate solution ; ( b ) mixing uniformly the ferric chloride , the potassium dichromate and the sodium carbonate obtained from step ( a ), heating to a heating temperature of 200 ° c . and maintaining for a time period of 9 min to obtain a mixture ; ( c ) adding the 5 ml of potassium persulfate solution ( 1 . 5 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 2 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 89 ˜ 93 %. according to a method of synthesizing ferrate composite pharmaceutical of this preferred embodiment of the present invention , the method comprises the following steps : ( a ) weight and obtain 2 . 5 g of ferric nitrate , 0 5 g of potassium dichromate , 2 . 2 g of potassium hydroxide and 5 ml of 1 . 5 mol / l hydrogen peroxide solution ; ( b ) mixing uniformly the ferric nitrate , the potassium dichromate and the potassium hydroxide obtained from step ( a ), heating to a heating temperature of 390 ° c . and maintaining for a time period of 20 min to obtain a mixture ; ( c ) adding the 5 ml of hydrogen peroxide solution ( 1 . 5 mol / l ) from step ( a ) to the mixture in the step ( b ) in which an adding time is controlled at less than 5 minute , and obtaining a precursor ; and ( d ) natural cooling the precursor obtained from step ( c ), then mixing the precursor with 5 ml of water and stirring evenly to obtain ferrate products , which is a ferrate composite pharmaceutical , where a yield of the ferrate products is 73 ˜ 78 %. one skilled in the art will understand that the embodiment of the present invention as shown in the drawings and described above is exemplary only and not intended to be limiting . it will thus be seen that the objects of the present invention have been fully and effectively accomplished . it embodiments have been shown and described for the purposes of illustrating the functional and structural principles of the present invention and is subject to change without departure from such principles . therefore , this invention includes all modifications encompassed within the spirit and scope of the following claims .
a method of synthesizing ferrate , which includes the steps of : weighing and obtaining iron salts , activating agents , alkalinizing agents and oxidizing agents solution ; mixing uniformly the iron salts , the activating agents and the alkalinizing agents , heating to 30 ˜ 398 ° c . and maintaining for 1 min ˜ 60 min to obtain a mixture ; adding the oxidizing agents solution to the mixture with an adding time of less than 10 minutes , then obtaining a precursor ; and natural cooling the precursor , then mixing the precursor with water and stirring evenly to obtain a final product of ferrate , wherein a volume ratio of the precursor and the water is 1 : 1 ˜ 5 . the method involves low power consumption , low temperature , low explosion risk , non - complicated steps and procedures , short synthetic time and high ferrate conversion efficiency . the method produces ferrate of high yield and good stability , and is suitable for producing ferrate composite pharmaceuticals in industrialized mass production .